Hervé Dombret

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 845 citations · Full text

Medicine, Hematology, Oncology +13

Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

Colette Adida, Corinne Haïoun, Philippe Gaulard et al. · PubMed · 2000 · 360 citations

Veterinary Medicine, Oncology, Pathology +11

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Sebastian Giebel et al. · Hematology · 2019 · 74 citations · Full text

Medicine, Hematology, Oncology +17

An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study

Jonathan Bond, Tony Marchand, Aurore Touzart et al. · Haematologica · 2016 · 60 citations · Full text

Medicine, Hematology, Oncology +17

BLAST: A Confirmatory, Single-Arm, Phase 2 Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Patients with Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia (ALL)

Nicola Goekbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2014 · 59 citations

Medicine, Hematology, Immunology +16